Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: J05AH03

Alpivab(peramivir)

Influenza, Human

Marketing Authorisation Holder: Biocryst

EMA Authorisation: 13/04/2018

INN: peramivir

Indication

Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Alpivab — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.